A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
نویسندگان
چکیده
IMPORTANCE A previous 2-year analysis of repeated rituximab treatment in patients with neuromyelitis optica (NMO) revealed significant improvements in relapse rates and disability. We report the findings from the longest follow-up of rituximab treatment in NMO, which provide reassurance regarding the long-term efficacy and safety of rituximab in NMO. OBJECTIVE To report the results of rituximab treatment in patients with relapsing NMO or NMO spectrum disorder (NMOSD) for a median of 60 months. DESIGN, SETTING, AND PARTICIPANTS Retrospective case series in an institutional referral center for multiple sclerosis, including 30 patients with relapsing NMO or NMOSD. INTERVENTIONS After induction therapy, a single infusion of rituximab (375 mg/m2) as maintenance therapy was administered whenever the frequency of reemerging CD27+ memory B cells in peripheral blood mononuclear cells, as measured with flow cytometry, exceeded 0.05%in the first 2 years and 0.1% thereafter. MAIN OUTCOMES AND MEASURES Annualized relapse rate (ARR), disability (Expanded Disability Status Scale score), change in anti–aquaporin 4 antibody, and safety of rituximab treatment. RESULTS Of 30 patients, 26 (87%) exhibited a marked reduction in ARR over 5 years (mean [SD] pretreatment vs posttreatment ARR, 2.4 [1.5] vs 0.3 [1.0]). Eighteen patients (60%) became relapse free after rituximab treatment. In 28 patients (93%), the disability was either improved or stabilized after rituximab treatment. No serious adverse events leading to discontinuation were observed during follow-up. CONCLUSIONS AND RELEVANCE Repeated treatment with rituximab in patients with NMOSD over a 5-period, using an individualized dosing schedule according to the frequency of reemerging CD27+ memory B cells, leads to a sustained clinical response with no new adverse events.
منابع مشابه
Tumefactive Brain Lesions in Patients with Neuromyelitis Optica Spectrum Disorder
Background: Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune neurological disorder that is characterized by optic neuritis and longitudinally-extended transverse myelitis lesions in spinal segments. Magnetic Resonance Imaging (MRI) findings are part of the diagnostic process in NMOSD patients, and abnormal lesion patterns may cause deviation from a correct diagnosis. Clinical P...
متن کاملEfficacy and Safety of Rituximab in patients with Neuromyelitis Optica Spectrum Disorders: A prospective observation in Iranian Cases.
متن کامل
The Impact of COVID-19 Pandemic on Neuromyelitis Optica Disorder Patients, After one Year
Background: Coronavirus Disease 2019 (COVID-19) recently created a pandemic with high mortality. People with underlying diseases are prone to severe infection. The nature of NMOSD disease and its treatment by immunosuppressants predisposes patients to infection. Objectives: This study aimed to evaluate the effect of the COVID-19 pandemic on the clinical course of NMOSD and the characteristi...
متن کاملRituximab as a first-line preventive treatment in pediatric NMOSDs
OBJECTIVE No established therapeutic protocol has been proposed to date for childhood-onset neuromyelitis optica (NMO) spectrum disorders (NMOSDs). We report the response of 5 NMO immunoglobulin (Ig)G-positive pediatric cases to a standardized B-cell-targeted first-line immunosuppressive protocol with rituximab for prevention of relapses. METHODS Retrospective observational cohort study. RE...
متن کاملO 14: Differentiating Demyelinating Disorders of the Central Nervous System – a Focus on Multiple Sclerosis and Neuromyelitis-Optica Spectrum Disorders
Significant advances have been made in diagnosis and therapy of demyelinating disorders of the central nervous system. The most common entities of this disorders in adults – multiple sclerosis and neuromyelitis optica were initially thought to be different phenotypes of more or less the same disease. During the last ten years, this view was subsequently changed and the term neuromyelitis ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- JAMA neurology
دوره 70 9 شماره
صفحات -
تاریخ انتشار 2013